Effectiveness of neoton in patients with heart failure receiving sacubitril/valsartan. Sub-analysis of the BYHEART study

Aim. To study the effectiveness of exogenous phosphocreatine (EP) therapy in patients with heart failure (HF) with reduced and mildly reduced ejection fraction (EF) receiving sacubitril/valsartan.Material and methods. The nationwide prospective observational study BYHEART included a total of 842 pat...

Full description

Saved in:
Bibliographic Details
Main Authors: S. N. Tereshchenko, A. A. Safiullina
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2024-06-01
Series:Российский кардиологический журнал
Subjects:
Online Access:https://russjcardiol.elpub.ru/jour/article/view/5917
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849341352161050624
author S. N. Tereshchenko
A. A. Safiullina
author_facet S. N. Tereshchenko
A. A. Safiullina
author_sort S. N. Tereshchenko
collection DOAJ
description Aim. To study the effectiveness of exogenous phosphocreatine (EP) therapy in patients with heart failure (HF) with reduced and mildly reduced ejection fraction (EF) receiving sacubitril/valsartan.Material and methods. The nationwide prospective observational study BYHEART included a total of 842 patients who underwent intravenous EP therapy. To achieve this goal, a group of patients was identified that received sacubitril/valsartan (n=139). Before and after the EP course, the following methods were used: the Minnesota Living with Heart Failure Questionnaire (MLHFQ), Rating Scale of Clinical State, transthoracic echocardiography assessing left ventricular EF (LVEF), 6-minute walk test (6MWT), assessment of NT-proBNP level.Results. Of the 139 patients included in the study, 69,06% (n=96) were male. The mean age was 62,89±12,2 years. Of the entire cohort of patients with HF, 50 patients had class II (35,97%), 80 — class III (57,56%), 9 — class IV (6,47%). EP therapy led to a significant improvement in the quality of life (from 67±17 to 49±16, p<0,01, delta -6,7), a decrease in the Rating Scale of Clinical State score (from 7,7±2,8 to 5,6±2,1, p<0,01, delta -2,2), an increase in 6MWT distance (from 261±85 m to 310±74 m, p<0,01, delta 49 m), LVEF (from 38,5±7,01% to 40,25±6,58%, p<0,01, delta 1,75%), decreased NT-proBNP concentration (from 1000 [602; 1869] pg/ml to 832 [469; 1614] pg/ml, p<0,01).Conclusion. The results obtained demonstrate that adjuvant intravenous mitochondrial EP therapy in patients with HF receiving sacubitril/valsartan improves quality of life, decrease the Rating Scale of Clinical State score and NT-proBNP concentration, as well as increase 6MWT distance and LVEF.
format Article
id doaj-art-4995bfce813947cbbabc6996b4e99ac4
institution Kabale University
issn 1560-4071
2618-7620
language Russian
publishDate 2024-06-01
publisher «FIRMA «SILICEA» LLC
record_format Article
series Российский кардиологический журнал
spelling doaj-art-4995bfce813947cbbabc6996b4e99ac42025-08-20T03:43:39Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202024-06-0129610.15829/1560-4071-2024-59174085Effectiveness of neoton in patients with heart failure receiving sacubitril/valsartan. Sub-analysis of the BYHEART studyS. N. Tereshchenko0A. A. Safiullina1Chazov National Medical Research Center of CardiologyChazov National Medical Research Center of CardiologyAim. To study the effectiveness of exogenous phosphocreatine (EP) therapy in patients with heart failure (HF) with reduced and mildly reduced ejection fraction (EF) receiving sacubitril/valsartan.Material and methods. The nationwide prospective observational study BYHEART included a total of 842 patients who underwent intravenous EP therapy. To achieve this goal, a group of patients was identified that received sacubitril/valsartan (n=139). Before and after the EP course, the following methods were used: the Minnesota Living with Heart Failure Questionnaire (MLHFQ), Rating Scale of Clinical State, transthoracic echocardiography assessing left ventricular EF (LVEF), 6-minute walk test (6MWT), assessment of NT-proBNP level.Results. Of the 139 patients included in the study, 69,06% (n=96) were male. The mean age was 62,89±12,2 years. Of the entire cohort of patients with HF, 50 patients had class II (35,97%), 80 — class III (57,56%), 9 — class IV (6,47%). EP therapy led to a significant improvement in the quality of life (from 67±17 to 49±16, p<0,01, delta -6,7), a decrease in the Rating Scale of Clinical State score (from 7,7±2,8 to 5,6±2,1, p<0,01, delta -2,2), an increase in 6MWT distance (from 261±85 m to 310±74 m, p<0,01, delta 49 m), LVEF (from 38,5±7,01% to 40,25±6,58%, p<0,01, delta 1,75%), decreased NT-proBNP concentration (from 1000 [602; 1869] pg/ml to 832 [469; 1614] pg/ml, p<0,01).Conclusion. The results obtained demonstrate that adjuvant intravenous mitochondrial EP therapy in patients with HF receiving sacubitril/valsartan improves quality of life, decrease the Rating Scale of Clinical State score and NT-proBNP concentration, as well as increase 6MWT distance and LVEF.https://russjcardiol.elpub.ru/jour/article/view/5917observational studyexogenous phosphocreatinesacubitril/valsartanheart failurequality of lifecardionis consortiumenrollme.ru digital platform
spellingShingle S. N. Tereshchenko
A. A. Safiullina
Effectiveness of neoton in patients with heart failure receiving sacubitril/valsartan. Sub-analysis of the BYHEART study
Российский кардиологический журнал
observational study
exogenous phosphocreatine
sacubitril/valsartan
heart failure
quality of life
cardionis consortium
enrollme.ru digital platform
title Effectiveness of neoton in patients with heart failure receiving sacubitril/valsartan. Sub-analysis of the BYHEART study
title_full Effectiveness of neoton in patients with heart failure receiving sacubitril/valsartan. Sub-analysis of the BYHEART study
title_fullStr Effectiveness of neoton in patients with heart failure receiving sacubitril/valsartan. Sub-analysis of the BYHEART study
title_full_unstemmed Effectiveness of neoton in patients with heart failure receiving sacubitril/valsartan. Sub-analysis of the BYHEART study
title_short Effectiveness of neoton in patients with heart failure receiving sacubitril/valsartan. Sub-analysis of the BYHEART study
title_sort effectiveness of neoton in patients with heart failure receiving sacubitril valsartan sub analysis of the byheart study
topic observational study
exogenous phosphocreatine
sacubitril/valsartan
heart failure
quality of life
cardionis consortium
enrollme.ru digital platform
url https://russjcardiol.elpub.ru/jour/article/view/5917
work_keys_str_mv AT sntereshchenko effectivenessofneotoninpatientswithheartfailurereceivingsacubitrilvalsartansubanalysisofthebyheartstudy
AT aasafiullina effectivenessofneotoninpatientswithheartfailurereceivingsacubitrilvalsartansubanalysisofthebyheartstudy